{"url_path":"/sec/cytk/8-k/2026-05-08/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1061983/0001193125-26-214606-index.html","accession_number":"0001193125-26-214606","cik":"0001061983","ticker":"CYTK","issuer_name":"CYTOKINETICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1061983/0001193125-26-214606-index.html","primary_entity_key":"0001061983","primary_entity_name":"CYTOKINETICS INC"},"word_count":129,"has_tables":true,"body_markdown":"ITEM 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n  \nDescription\n\n 1.1\n  \n[Underwriting Agreement, dated as of May 6, 2026, by and among Cytokinetics, Incorporated, Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC.](d138544dex11.htm)\n\n 5.1\n  \n[Opinion of Gibson, Dunn & Crutcher LLP.](d138544dex51.htm)\n\n23.1\n  \n[Consent of Gibson, Dunn & Crutcher LLP (contained in Exhibit 5.1).](d138544dex51.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nCYTOKINETICS, INCORPORATED\n\nDate: May 8, 2026\n \n\n \nBy:\n \n\n/s/ John O. Faurescu\n\n \n\n \n\n \nJohn O. Faurescu\n\n \n\n \n\n \n\nSenior Vice President, Deputy\n\nGeneral Counsel and Corporate Secretary"}